{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:41:08Z","timestamp":1784673668424,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014131","name":"McGill University Health Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014131","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015015","name":"Government of South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ekir.2022.03.032","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T19:41:43Z","timestamp":1649274103000},"page":"1332-1340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hydralazine\u2013Isosorbide Dinitrate Use in Patients With End-Stage Kidney Disease on Dialysis"],"prefix":"10.1016","volume":"7","author":[{"given":"Thomas A.","family":"Mavrakanas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qandeel H.","family":"Soomro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Charytan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2022.03.032_bib1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/MNH.0000000000000280","article-title":"Cardiovascular complications in chronic dialysis patients","volume":"25","author":"Mavrakanas","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ekir.2022.03.032_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MNH.0b013e3282f313bd","article-title":"Cardiovascular disease in dialysis patients: do some antihypertensive drugs have specific antioxidant effects or is it just blood pressure reduction? Does antioxidant treatment reduce the risk for cardiovascular disease?","volume":"17","author":"Aslam","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ekir.2022.03.032_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1074248415587969","article-title":"Direct vasodilators and sympatholytic agents","volume":"21","author":"McComb","year":"2016","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ekir.2022.03.032_bib5","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1172\/JCI200524408","article-title":"Oxygen, oxidative stress, hypoxia, and heart failure","volume":"115","author":"Giordano","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2022.03.032_bib6","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1161\/01.RES.0000129569.07667.89","article-title":"Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart","volume":"94","author":"Prabhu","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.ekir.2022.03.032_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.intimp.2003.10.004","article-title":"Antioxidant activity and inhibitory effects of hydralazine on inducible NOS\/COX-2 gene and protein expression in rat peritoneal macrophages","volume":"4","author":"Leiro","year":"2004","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ekir.2022.03.032_bib8","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1172\/JCI118935","article-title":"Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug","volume":"98","author":"M\u00fcnzel","year":"1996","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2022.03.032_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.03.032_bib10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1071-9164(99)90001-5","article-title":"Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group","volume":"5","author":"Carson","year":"1999","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.ekir.2022.03.032_bib11","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure [published correction appears in N Engl J Med. 2005 Mar 24;352(12):1276]","volume":"351","author":"Taylor","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.03.032_bib12","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1161\/CIRCULATIONAHA.110.012781","article-title":"Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions","volume":"123","author":"Cole","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2022.03.032_bib14","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/aje\/kwi307","article-title":"Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods","volume":"162","author":"Zhou","year":"2005","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ekir.2022.03.032_bib16","first-page":"236","article-title":"Improvement of hypertension and LVH in maintenance hemodialysis patients treated with sustained-release isosorbide mononitrate","volume":"24","author":"Li","year":"2011","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2022.03.032_bib15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores","volume":"54","author":"Normand","year":"2001","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ekir.2022.03.032_bib17","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3390\/ijms14011069","article-title":"Organic nitrates favor regression of left ventricular hypertrophy in hypertensive patients on chronic peritoneal dialysis","volume":"14","author":"Li","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2022.03.032_bib18","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.34067\/KID.0004342020","article-title":"Combination hydralazine and isosorbide dinitrate in dialysis-dependent ESRD (HIDE): a randomized, placebo-controlled, pilot trial","volume":"1","author":"Charytan","year":"2020","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2022.03.032_bib19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrcardio.2017.224","article-title":"Nitric oxide signalling in cardiovascular health and disease","volume":"15","author":"Farah","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ekir.2022.03.032_bib20","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00424.2007","article-title":"Nitric oxide deficiency in chronic kidney disease","volume":"294","author":"Baylis","year":"2008","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.ekir.2022.03.032_bib21","doi-asserted-by":"crossref","first-page":"F275","DOI":"10.1152\/ajprenal.00020.2019","article-title":"Reduced endothelial nitric oxide synthase activation contributes to cardiovascular injury during chronic kidney disease progression","volume":"317","author":"Amador-Mart\u00ednez","year":"2019","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.ekir.2022.03.032_bib22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5830\/CVJA-2011-068","article-title":"Endothelial dysfunction: the early predictor of atherosclerosis","volume":"23","author":"Mudau","year":"2012","journal-title":"Cardiovasc J Afr"},{"key":"10.1016\/j.ekir.2022.03.032_bib23","doi-asserted-by":"crossref","first-page":"FSO48","DOI":"10.4155\/fso.15.48","article-title":"Nitric oxide enhancement strategies","volume":"1","author":"Bryan","year":"2015","journal-title":"Future Sci OA"},{"key":"10.1016\/j.ekir.2022.03.032_bib24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000338150","article-title":"Characterization of the role of nitric oxide and its clinical applications","volume":"122","author":"Levine","year":"2012","journal-title":"Cardiology"},{"key":"10.1016\/j.ekir.2022.03.032_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4161\/oxim.2.5.9441","article-title":"Oxidative stress as a mediator of cardiovascular disease","volume":"2","author":"Elahi","year":"2009","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.ekir.2022.03.032_bib26","doi-asserted-by":"crossref","first-page":"25i","DOI":"10.1016\/j.amjcard.2005.07.030","article-title":"The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine","volume":"96","author":"Daiber","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ekir.2022.03.032_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2165\/00003088-198916020-00003","article-title":"Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure","volume":"16","author":"Mulrow","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ekir.2022.03.032_bib28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1525-139X.2009.00697.x","article-title":"Antihypertensive agents in hemodialysis patients: a current perspective","volume":"23","author":"Inrig","year":"2010","journal-title":"Semin Dial"},{"key":"10.1016\/j.ekir.2022.03.032_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922012529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922012529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:41:13Z","timestamp":1762832473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024922012529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2468024922012529"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2022.03.032","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydralazine\u2013Isosorbide Dinitrate Use in Patients With End-Stage Kidney Disease on Dialysis","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2022.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}